Literature DB >> 10644369

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

P D Kwong1, R Wyatt, Q J Sattentau, J Sodroski, W A Hendrickson.   

Abstract

The human immunodeficiency virus envelope glycoproteins, gp120 and gp41, function in cell entry by binding to CD4 and a chemokine receptor on the cell surface and orchestrating the direct fusion of the viral and target cell membranes. On the virion surface, three gp120 molecules associate noncovalently with the ectodomain of the gp41 trimer to form the envelope oligomer. Although an atomic-level structure of a monomeric gp120 core has been determined, the structure of the oligomer is unknown. Here, the orientation of gp120 in the oligomer is modeled by using quantifiable criteria of carbohydrate exposure, occlusion of conserved residues, and steric considerations with regard to the binding of the neutralizing antibody 17b. Applying similar modeling techniques to influenza virus hemagglutinin suggests a rotational accuracy for the oriented gp120 of better than 10 degrees. The model shows that CD4 binds obliquely, such that multiple CD4 molecules bound to the same oligomer have their membrane-spanning portions separated by at least 190 A. The chemokine receptor, in contrast, binds to a sterically restricted surface close to the trimer axis. Electrostatic analyses reveal a basic region which faces away from the virus, toward the target cell membrane, and is conserved on core gp120. The electrostatic potentials of this region are strongly influenced by the overall charge, but not the precise structure, of the third variable (V3) loop. This dependence on charge and not structure may make electrostatic interactions between this basic region and the cell difficult to target therapeutically and may also provide a means of viral escape from immune system surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644369      PMCID: PMC111674          DOI: 10.1128/jvi.74.4.1961-1972.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

2.  Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.

Authors:  I Mondor; S Ugolini; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Electrostatics and the membrane association of Src: theory and experiment.

Authors:  D Murray; L Hermida-Matsumoto; C A Buser; J Tsang; C T Sigal; N Ben-Tal; B Honig; M D Resh; S McLaughlin
Journal:  Biochemistry       Date:  1998-02-24       Impact factor: 3.162

4.  A basic compositional requirement of agents having heparin-like cell-modulating activities.

Authors:  P B Weisz; M M Joullié; C M Hunter; K M Kumor; Z Zhang; E Levine; E Macarak; D Weiner; E S Barnathan
Journal:  Biochem Pharmacol       Date:  1997-07-01       Impact factor: 5.858

5.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

6.  Structure and polymorphism of HIV-1 third variable loops.

Authors:  P Catasti; E M Bradbury; G Gupta
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

7.  Capture of an early fusion-active conformation of HIV-1 gp41.

Authors:  R A Furuta; C T Wild; Y Weng; C D Weiss
Journal:  Nat Struct Biol       Date:  1998-04

8.  A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.

Authors:  M Farzan; H Choe; L Vaca; K Martin; Y Sun; E Desjardins; N Ruffing; L Wu; R Wyatt; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Authors:  T Dragic; A Trkola; S W Lin; K A Nagashima; F Kajumo; L Zhao; W C Olson; L Wu; C R Mackay; G P Allaway; T P Sakmar; J P Moore; P J Maddon
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs.

Authors:  R Staudinger; N G Abraham; R D Levere; A Kappas
Journal:  Proc Assoc Am Physicians       Date:  1996-01
View more
  113 in total

1.  Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Authors:  P Zhu; W C Olson; K H Roux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Authors:  T R Fouts; R Tuskan; K Godfrey; M Reitz; D Hone; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase.

Authors:  Bing Chen; Yifan Cheng; Lesley Calder; Stephen C Harrison; Ellis L Reinherz; John J Skehel; Don C Wiley
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

9.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.